{"id":"efalizumab-raptiva","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Worsening psoriasis"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201575","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efalizumab binds to CD11a (the alpha subunit of lymphocyte function-associated antigen-1, LFA-1) on T lymphocytes, inhibiting their interaction with intercellular adhesion molecule-1 (ICAM-1) on endothelial cells and antigen-presenting cells. This prevents T cell activation, proliferation, and migration into inflamed tissue, thereby reducing the pathogenic immune response in psoriasis.","oneSentence":"Efalizumab is a monoclonal antibody that blocks CD11a on T cells, preventing their activation and migration to the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:04.033Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT02075697","phase":"","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","startDate":"2008-10","conditions":"Psoriasis","enrollment":3500},{"nctId":"NCT00115076","phase":"PHASE3","title":"Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2003-08-04","conditions":"Psoriasis","enrollment":31},{"nctId":"NCT00501709","phase":"PHASE1, PHASE2","title":"Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-02","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT00308204","phase":"PHASE2","title":"Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2006-03","conditions":"Discoid Lupus Erthematosus of the Scalp","enrollment":""},{"nctId":"NCT00226057","phase":"PHASE1","title":"Efalizumab for Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2005-06","conditions":"Dermatitis, Atopic","enrollment":10},{"nctId":"NCT00368654","phase":"PHASE1, PHASE2","title":"Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2007-01","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT00287118","phase":"PHASE4","title":"A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-10-27","conditions":"Candidates for Systemic Therapy for Psoriasis, Psoriasis","enrollment":189},{"nctId":"NCT00249808","phase":"PHASE4","title":"A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-12-13","conditions":"Psoriasis","enrollment":1266},{"nctId":"NCT00672204","phase":"PHASE1, PHASE2","title":"Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2007-11","conditions":"Type 1 Diabetes Mellitus, Hypoglycemia","enrollment":23},{"nctId":"NCT00729768","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation","status":"WITHDRAWN","sponsor":"Genentech, Inc.","startDate":"","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT00669214","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-02","conditions":"Psoriasis","enrollment":89},{"nctId":"NCT00489216","phase":"NA","title":"Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-12","conditions":"Graft Versus Host Disease","enrollment":2},{"nctId":"NCT00312026","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03-30","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT00256139","phase":"PHASE3","title":"CLEAR Study: Clinical Experience Acquired With Raptiva Study","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2003-03","conditions":"Moderate to Severe Psoriasis","enrollment":793},{"nctId":"NCT00442650","phase":"PHASE3","title":"Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-01","conditions":"Moderate to Severe Psoriasis","enrollment":""},{"nctId":"NCT00676559","phase":"PHASE1","title":"Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-04","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00276250","phase":"PHASE2","title":"Islet Transplantation Using Abatacept","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-12","conditions":"Type 1 Diabetes Mellitus","enrollment":5},{"nctId":"NCT00746980","phase":"PHASE2","title":"Efalizumab in the Treatment of Alopecia, Phase II","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":"Alopecia Totalis","enrollment":""},{"nctId":"NCT00344448","phase":"PHASE2","title":"Pilot Study of Raptiva to Treat Sjogren's Syndrome","status":"TERMINATED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2006-06","conditions":"Sjogren's Syndrome","enrollment":10},{"nctId":"NCT00254982","phase":"PHASE3","title":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Psoriasis","enrollment":593},{"nctId":"NCT00336973","phase":"PHASE4","title":"A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-05","conditions":"Psoriasis","enrollment":73},{"nctId":"NCT00726466","phase":"PHASE1","title":"Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Vitreous -Retina- Macula Consultants of New York","startDate":"2008-03","conditions":"Age Related Macular Degeneration, AMD, CNV","enrollment":""},{"nctId":"NCT00096928","phase":"","title":"A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-03","conditions":"Psoriasis","enrollment":1846},{"nctId":"NCT00402818","phase":"","title":"RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-05","conditions":"Plaque Psoriasis","enrollment":294},{"nctId":"NCT00737763","phase":"PHASE2","title":"Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2008-10","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT00096603","phase":"PHASE3","title":"A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-10","conditions":"Psoriasis","enrollment":450},{"nctId":"NCT00338143","phase":"PHASE3","title":"A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-10","conditions":"Psoriasis","enrollment":1200},{"nctId":"NCT00739882","phase":"PHASE4","title":"TRUST Study: Raptiva ® in Hand & Foot Psoriasis","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-04","conditions":"Chronic Plaque Psoriasis","enrollment":76},{"nctId":"NCT01079988","phase":"PHASE4","title":"Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-02","conditions":"Psoriasis","enrollment":41},{"nctId":"NCT00697593","phase":"PHASE4","title":"ChangE From Any Systemic psoriasiS therapY to Raptiva","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-01","conditions":"Chronic Plaque Psoriasis","enrollment":70},{"nctId":"NCT00972543","phase":"PHASE4","title":"Raptiva in Palm and Sole Psoriasis","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-09","conditions":"Chronic Plaque Psoriasis","enrollment":6},{"nctId":"NCT00472082","phase":"PHASE1, PHASE2","title":"Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Emory University","startDate":"2007-05","conditions":"Kidney Transplantation, Chronic Kidney Failure","enrollment":5},{"nctId":"NCT00096980","phase":"PHASE4","title":"A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2001-02","conditions":"Psoriasis","enrollment":300},{"nctId":"NCT00109252","phase":"PHASE3","title":"A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-01","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT00109317","phase":"PHASE3","title":"A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-09","conditions":"Psoriasis","enrollment":686},{"nctId":"NCT00777400","phase":"PHASE1, PHASE2","title":"Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2008-12","conditions":"Autoimmune Diseases","enrollment":""},{"nctId":"NCT00608777","phase":"PHASE4","title":"Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)","status":"TERMINATED","sponsor":"Derm Research, PLLC","startDate":"2008-01","conditions":"Plaque Psoriasis","enrollment":6},{"nctId":"NCT00184366","phase":"","title":"Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis","status":"TERMINATED","sponsor":"Norwegian University of Science and Technology","startDate":"2005-05","conditions":"Plaque Psoriasis","enrollment":96},{"nctId":"NCT00133107","phase":"NA","title":"Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2005-01","conditions":"Lichen Planus, Oral","enrollment":4},{"nctId":"NCT00280826","phase":"PHASE1","title":"Efalizumab to Treat Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2006-01","conditions":"Uveitis, Macular Edema","enrollment":6},{"nctId":"NCT00097240","phase":"","title":"An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-01","conditions":"Psoriasis, Pregnancy","enrollment":18},{"nctId":"NCT00510536","phase":"PHASE4","title":"Treatment of Mild to Moderate Joint Pain in Patients With Chronic Plaque Psoriasis Receiving Efalizumab","status":"COMPLETED","sponsor":"Probity Medical Research","startDate":"2007-07","conditions":"Arthritis, Arthralgia","enrollment":50},{"nctId":"NCT00146003","phase":"PHASE2","title":"Efalizumab for Eczema","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-03","conditions":"Dermatitis, Atopic","enrollment":10},{"nctId":"NCT00707070","phase":"PHASE4","title":"Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2008-09","conditions":"Chronic Plaque Psoriasis","enrollment":100},{"nctId":"NCT00602823","phase":"","title":"Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-02","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT00302445","phase":"PHASE4","title":"A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2006-03","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT00382512","phase":"PHASE1","title":"A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-05","conditions":"Plaque Psoriasis","enrollment":60},{"nctId":"NCT00134134","phase":"PHASE1","title":"Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2005-02","conditions":"Hidradenitis Suppurativa","enrollment":5},{"nctId":"NCT00034203","phase":"PHASE2","title":"Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"XOMA (US) LLC","startDate":"2002-04","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00051662","phase":"PHASE1","title":"Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis","status":"COMPLETED","sponsor":"XOMA (US) LLC","startDate":"","conditions":"Psoriatic Arthritis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Raptiva"],"phase":"marketed","status":"active","brandName":"Efalizumab (Raptiva)","genericName":"Efalizumab (Raptiva)","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Biologic","firstApprovalDate":"","aiSummary":"Efalizumab is a monoclonal antibody that blocks CD11a on T cells, preventing their activation and migration to the skin. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}